HRP20120989T1 - Peptidi koji se vežu za receptor eritropoetina - Google Patents
Peptidi koji se vežu za receptor eritropoetina Download PDFInfo
- Publication number
- HRP20120989T1 HRP20120989T1 HRP20120989TT HRP20120989T HRP20120989T1 HR P20120989 T1 HRP20120989 T1 HR P20120989T1 HR P20120989T T HRP20120989T T HR P20120989TT HR P20120989 T HRP20120989 T HR P20120989T HR P20120989 T1 HRP20120989 T1 HR P20120989T1
- Authority
- HR
- Croatia
- Prior art keywords
- peptide
- peg
- peptide dimer
- daltons
- molecular weight
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 58
- 108010075944 Erythropoietin Receptors Proteins 0.000 title claims 3
- 102100036509 Erythropoietin receptor Human genes 0.000 title claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 2
- 239000000539 dimer Substances 0.000 claims 25
- 229920001223 polyethylene glycol Polymers 0.000 claims 19
- 239000002202 Polyethylene glycol Substances 0.000 claims 17
- 229920003169 water-soluble polymer Polymers 0.000 claims 6
- 150000001413 amino acids Chemical group 0.000 claims 3
- 208000007502 anemia Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 claims 1
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 claims 1
- KFHRMMHGGBCRIV-BYPYZUCNSA-N (2s)-2-azaniumyl-4-methoxybutanoate Chemical compound COCC[C@H](N)C(O)=O KFHRMMHGGBCRIV-BYPYZUCNSA-N 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 208000005980 beta thalassemia Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 230000010437 erythropoiesis Effects 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Claims (37)
1. Peptid s 17 do 40 aminokiselinskih ostataka u dužini koji sadrži sekvencu aminokiselina:
LYACHX0GPITX1VCQPLR (SEQ ID NO: 1),
gdje je X0 ostatak izabran između metionina (M) i homoserin metiletera (Hsm), i X1 je ostatak izabran između triptofana (W), 1-naftilalanina (1-nal), i 2-naftilalanina (2-nal),
gdje se taj peptid veže za i aktivira receptor eritropoetina (EPO-R).
2. Peptid prema zahtjevu 1, gdje je N-kraj tog peptida acetiliran.
3. Peptid prema zahtjevu 1 ili zahtjevu 2, taj peptid sadrži sekvencu aminokiselina izabranu između:
[image]
[image]
4. Peptid prema bilo kojem od zahtjeva 1 do 3, gdje je peptid monomer.
5. Peptid prema bilo kojem od zahtjeva 1 do 4, koji dalje sadrži jedan ili više polimera topljivih u vodi koji su kovalentno povezani s peptidom.
6. Peptid prema zahtjevu 5, gdje je polimer topljiv u vodi polietilenglikol (PEG).
7. Peptid prema zahtjevu 6, gdje taj PEG sarži linearnu nerazgranatu molekulu s molekularnom težinom od 500 do 60,000 Daltona.
8. Peptid prema zahtjevu 7, gdje PEG ima molekularnu težinu manju od 20,000 Daltona.
9. Peptid prema zahtjevu 7, gdje PEG ima molekularnu težinu od 20,000 do 60,000 Daltona.
10. Peptid prema bilo kojem od zahtjeva 6-7 i 9, gdje PEG ima molekularnu težinu od 20,000 do 40,000 Daltona.
11. Peptid prema zahtjevu 7, gdje su dvije PEG jedinke kovalentno vezane za peptid, svaki od tih PEG sadrži linearnu nerazgranatu molekulu.
12. Peptid prema zahtjevu 11, gdje svaki PEG ima molekularnu težinu od 20,000d 30,000 Daltona.
13. Peptidni dimer koji sadrži dva monomera, oba ta monomera su peptid prema bilo kojem od zahtjeva 1 do 3 i 5 do 12.
14. Peptidni dimer prema zahtjevu 13, gdje je peptid homodimer.
15. Peptidni dimer prema zahtjevu 13, sadrži:
(a) prvi peptidni lanac;
(b) drugi peptidni lanac; i
(c) povezujuću jedinku koja spaja prvi i drugi peptidni lanac,
gdje su oba, i prvi peptidni lanac i drugi peptidni lanac, peptidi prema zahtjevu 1.
16. Peptidni dimer prema zahtjevu 15, gdje barem jedan od prvog peptidnog lanca i drugog peptidnog lanca sadrži sekvencu aminokiselina izabranu između:
[image]
[image]
17. Peptidni dimer prema zahtjevu 15, gdje povezujuća jedinka obuhvaća formulu:
-NH-R3-NH-
gdje R3 je C1-6 alkilen.
18. Peptidni dimer prema zahtjevu 17, gdje je povezujuća jedinka ostatak lizina.
19. Peptidni dimer prema zahtjevu 15, gdje povezujuća jedinka obuhvaća formulu:
-CO-(CH2)n-X-(CH2)m-CO-
gdje je n cijeli broj od 0 do je cijeli broj od 1 do 10, X se izabire između O, S, N(CH2)pNR1, NCO(CH2)pNR1, i CHNR1, R1 se izabire između H, Boc, i Cbz, i p je cijeli broj od 1 do 10.
20. Peptidni dimer prema zahtjevu 19, gdje su n i m svaki 1, X je NCO(CH2)pNR1, p je 2, i R1 je H.
21. Peptidni dimer prema zahtjevu 15, dalje sadrži u vodi topljivi polimer.
22. Peptidni dimer prema zahtjevu 21, gdje je u vodi topljivi polimer kovalentno vezan za povezujuću jedinku.
23. Peptidni dimer prema zahtjevu 15, dalje sadrži razmaknicu.
24. Peptidni dimer prema zahtjevu 23, gdje razmaknica obuhvaća formulu:
-NH-(CH2)α-[O-(CH2)β]γ-Oδ-(CH2)ε-Y-
gdje α, β, i ε su cijeli brojevi čije su vrijednosti nezavisno izabrane između 1 do 6, δ je 0 ili 1, γ je cijeli broj izabran između 0 do 10, i Y je izabran između NH ili CO, uz uvjet da je 2 kada je γ veći od 1.
25. Peptidni dimer prema zahtjevu 24 gdje je svaki od α, β, i ε jednak 2, svaki od γ i δ je 1, i Y je NH.
26. Peptidni dimer prema zahtjevu 23, dalje sadrži jedan ili više u vodi topljivih polimera.
27. Peptidni dimer prema zahtjevu 26, gdje je u vodi topljivi polimer kovalentno vezan za razmaknicu.
28. Peptidni dimer prema zahtjevu 21 ili 26, gdje je u vodi topljivi polimer polietilenglikol (PEG).
29. Peptidni dimer prema zahtjevu 28, gdje PEG je linearni nerazgranati PEG s molekularnom težinom od 500 do 60,000 Daltona.
30. Peptidni dimer prema zahtjevu 28 ili 29, gdje PEG ima molekularnu težinu od 500 do manje od 20,000 Daltona.
31. Peptidni dimer prema zahtjevu 28 ili 29, gdje PEG ima molekularnu težinu od 20,000 do 60,000 Daltona.
32. Peptidni dimer prema zahtjevu 28, 29 ili 31, gdje PEG ima molekularnu težinu od 20,000 do 40,000 Daltona.
33. Peptidni dimer prema zahtjevu 28, gdje su dvije PEG jedinke kovalentno vezane za peptid, svaki od tih PEG sadrži linearnu nerazgranatu molekulu.
34. Peptidni dimer prema zahtjevu 33, gdje svaki PEG ima molekularnu težinu od 20,000 do 30,000 Daltona.
35. Peptid ili peptidni dimer prema bilo kojem od zahtjeva 1 do 34 za uporabu u liječenju poremećaja naznačenog manjkom eritropoetina ili niskom ili manjkavom populacijom crvenih krvnih stanica.
36. Peptid ili peptidni dimer za uporabu prema zahtjevu 35, gdje se poremećaj izabire iz skupine koja obuhvaća: zadnji stupanj zatajenja bubrega ili dijaliza; anemija povezana s AIDS-om, autoimunom bolesti ili malignitetom; betatalasemija; cistična fibroza; rana anemija preuranjene zrelosti; anemija povezana s kroničnom inflamatornom bolesti; ozljeda leđne moždine; akutni gubitak krvi; starenje; i stanja neoplastične bolesti praćena abnormalnom eritropoezom.
37. Farmaceutski oblik koji sadrži:
(i) peptid ili peptidni dimer prema bilo kojem od zahtjeva 1 do 34; i
(ii) farmaceutski prihvatljivi nosač.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47024503P | 2003-05-12 | 2003-05-12 | |
PCT/US2004/014886 WO2004101611A2 (en) | 2003-05-12 | 2004-05-12 | Peptides that bind to the erythropoietin receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120989T1 true HRP20120989T1 (hr) | 2013-01-31 |
Family
ID=33452385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120989TT HRP20120989T1 (hr) | 2003-05-12 | 2012-12-03 | Peptidi koji se vežu za receptor eritropoetina |
Country Status (23)
Country | Link |
---|---|
US (4) | US7528104B2 (hr) |
EP (1) | EP1625156B1 (hr) |
JP (1) | JP4949844B2 (hr) |
KR (2) | KR101227666B1 (hr) |
CN (1) | CN1823088B (hr) |
AU (1) | AU2004238868B2 (hr) |
BR (1) | BRPI0411172A (hr) |
CA (1) | CA2525497A1 (hr) |
DK (1) | DK1625156T3 (hr) |
EA (1) | EA010099B1 (hr) |
ES (1) | ES2395413T3 (hr) |
HK (1) | HK1088906A1 (hr) |
HR (1) | HRP20120989T1 (hr) |
IL (1) | IL198844A0 (hr) |
IS (1) | IS8167A (hr) |
MX (1) | MXPA05012313A (hr) |
NO (1) | NO20055847L (hr) |
NZ (1) | NZ543935A (hr) |
PL (1) | PL1625156T3 (hr) |
PT (1) | PT1625156E (hr) |
SI (1) | SI1625156T1 (hr) |
WO (1) | WO2004101611A2 (hr) |
ZA (1) | ZA200509971B (hr) |
Families Citing this family (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7259146B2 (en) | 2000-05-26 | 2007-08-21 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroprotective peptides |
CA2525464A1 (en) * | 2003-05-12 | 2004-11-25 | Qun Yin | Novel poly(ethylene glycol) modified compounds and uses thereof |
WO2004101606A2 (en) * | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
EP2204193A3 (en) * | 2003-05-12 | 2010-08-18 | Affymax, Inc. | Novel spacer moiety for poly(ethylene glycol)-modified peptide-based compounds |
US20060228331A1 (en) * | 2003-10-10 | 2006-10-12 | Novo Nordisk A/S | IL-21 Derivatives and variants |
ES2428358T3 (es) * | 2003-10-17 | 2013-11-07 | Novo Nordisk A/S | Terapia de combinación |
US7589063B2 (en) | 2004-12-14 | 2009-09-15 | Aplagen Gmbh | Molecules which promote hematopoiesis |
JP2008538290A (ja) * | 2005-04-18 | 2008-10-23 | ノボ ノルディスク アクティーゼルスカブ | Il−21変異体 |
US7550433B2 (en) | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
WO2009025957A1 (en) * | 2007-08-22 | 2009-02-26 | Takeda Pharmaceuticals Company Limited | Erythropoietin receptor peptide formulations and uses |
US7919461B2 (en) * | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US8324159B2 (en) | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US20090042790A1 (en) * | 2005-06-13 | 2009-02-12 | Nastech Pharmaceutical Company Inc. | Transmucosal delivery of peptide derivatives |
EP3669894A3 (en) | 2006-06-30 | 2020-08-26 | Syntab Therapeutics GmbH | Novel multifunctional compounds for pharmaceutical purposes |
EP2091968A2 (en) | 2006-10-26 | 2009-08-26 | Novo Nordisk A/S | Il-21 variants |
WO2008049227A1 (en) | 2006-10-27 | 2008-05-02 | Sunnybrook Health Sciences Center | Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis |
CA2671665A1 (en) * | 2006-12-21 | 2008-06-26 | Novo-Nordisk A/S | Interleukin-21 variants with altered binding to the il-21 receptor |
JP2010520855A (ja) | 2007-01-31 | 2010-06-17 | アフィーマックス・インコーポレイテッド | 修飾基をポリペプチドおよびその他の高分子に結合するための窒素ベースのリンカー |
US20090131317A1 (en) * | 2007-06-22 | 2009-05-21 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
EP2018835B1 (de) | 2007-07-09 | 2014-03-05 | Augustinus Bader | Wirkstoff abgebendes Pflaster |
WO2009043049A2 (en) | 2007-09-27 | 2009-04-02 | Amgen Inc. | Pharmaceutical formulations |
EP2219602A1 (en) | 2007-11-15 | 2010-08-25 | Amgen, Inc | Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
CN101456911A (zh) * | 2007-12-12 | 2009-06-17 | 江苏豪森药业股份有限公司 | 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途 |
CN101978266A (zh) * | 2008-01-04 | 2011-02-16 | 拜尔特菲克斯有限公司 | 用于非共价增强受体结合的方法和组合物 |
JP5701064B2 (ja) | 2008-01-25 | 2015-04-15 | アムジエン・インコーポレーテツド | フェロポーチン抗体およびその使用方法 |
JP2009191056A (ja) * | 2008-02-15 | 2009-08-27 | Affymax Inc | 合成ペプチドをベースとするepoレセプターアゴニストを用いた抗エリスロポエチン抗体に媒介された障害の治療 |
ES2487846T3 (es) | 2008-05-01 | 2014-08-25 | Amgen, Inc. | Anticuerpos anti-hepcindina y métodos de uso |
CA2742871C (en) | 2008-11-13 | 2018-10-23 | Herb Lin | Methods and compositions for regulating iron homeostasis by modulation of bmp-6 |
WO2011012306A2 (en) | 2009-07-30 | 2011-02-03 | Aplagen Gmbh | Use of emps for antagonising epo-stimulatory effects on epo-responsive tumors while maintaining erythropoiesis |
US9662271B2 (en) | 2009-10-23 | 2017-05-30 | Amgen Inc. | Vial adapter and system |
WO2011156373A1 (en) | 2010-06-07 | 2011-12-15 | Amgen Inc. | Drug delivery device |
ES2632164T3 (es) | 2010-07-06 | 2017-09-11 | Augustinus Bader | Aplicación tópica de eritropoyetina para uso en el tratamiento de lesiones de la córnea |
MX341790B (es) | 2011-03-31 | 2016-09-02 | Amgen Inc | Adaptador de viales y sistema. |
PT2699293T (pt) | 2011-04-20 | 2019-05-21 | Amgen Inc | Aparelho de autoinjeção |
PL2574357T3 (pl) * | 2011-09-28 | 2014-04-30 | Q Med Ab | Iniektor elektroniczny |
IL308846A (en) | 2011-10-14 | 2024-01-01 | Amgen Inc | Syringe and assembly method |
CN103421094A (zh) * | 2012-05-24 | 2013-12-04 | 上海医药工业研究院 | 一种具有epo类似活性的多肽化合物 |
CN103450348B (zh) * | 2012-05-29 | 2016-03-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种促红细胞生成素模拟肽、其制备方法和用途 |
AU2013348071B2 (en) | 2012-11-21 | 2018-05-24 | Amgen Inc. | Drug delivery device |
KR102218494B1 (ko) | 2013-03-15 | 2021-02-19 | 인트린식 라이프사이언시스, 엘엘씨 | 항-헵시딘 항체 및 그의 용도 |
TWI580452B (zh) | 2013-03-15 | 2017-05-01 | 安美基公司 | 用於注射器之匣盒、注射器及使用包括自動注射器及匣盒之設備之方法 |
WO2014144096A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
ES2853748T3 (es) | 2013-03-22 | 2021-09-17 | Amgen Inc | Inyector y método de montaje |
ES2744837T3 (es) | 2013-10-24 | 2020-02-26 | Amgen Inc | Inyector y procedimiento de ensamblaje |
AU2014340174B2 (en) | 2013-10-24 | 2019-09-12 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
KR102496507B1 (ko) | 2014-05-07 | 2023-02-03 | 암겐 인코포레이티드 | 충격 감소 요소들을 가진 자동 주사기 |
IL297356A (en) | 2014-06-03 | 2022-12-01 | Amgen Inc | Controllable drug delivery system and method of use |
US10323088B2 (en) | 2014-09-22 | 2019-06-18 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
CA2957960C (en) | 2014-10-14 | 2023-08-22 | Amgen, Inc. | Drug injection device with visual and audible indicators |
ES2785311T3 (es) | 2014-12-19 | 2020-10-06 | Amgen Inc | Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario |
US10799630B2 (en) | 2014-12-19 | 2020-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
CA2976935C (en) | 2015-02-17 | 2020-03-10 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
EP3981450A1 (en) | 2015-02-27 | 2022-04-13 | Amgen, Inc | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
CN106554394B (zh) * | 2015-09-30 | 2019-08-16 | 天津药物研究院有限公司 | 一种促红细胞生成素模拟肽及其制备方法和应用 |
CN106608913B (zh) * | 2015-10-22 | 2020-05-05 | 天津药物研究院有限公司 | 一种1,2,3-丙三酸偶联的epo拟肽衍生物及其制备方法和应用 |
CN106608911B (zh) * | 2015-10-22 | 2020-01-07 | 天津药物研究院有限公司 | 一种二硫键修饰的epo拟肽衍生物及其制备方法和应用 |
WO2017100501A1 (en) | 2015-12-09 | 2017-06-15 | Amgen Inc. | Auto-injector with signaling cap |
CN106928338A (zh) * | 2015-12-31 | 2017-07-07 | 杭州阿德莱诺泰制药技术有限公司 | 促红细胞生成素肽及衍生物和聚合物、制备方法和应用 |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
US20180092770A1 (en) * | 2016-03-14 | 2018-04-05 | Virchow Biotech Pvt. Ltd. | Sterile protective cover comprising a device for opthalmic delivery |
US20170258633A1 (en) * | 2016-03-14 | 2017-09-14 | Virchow Biotech Pvt. Ltd. | Novel device for ophthalmic delivery |
ES2814287T3 (es) | 2016-03-15 | 2021-03-26 | Amgen Inc | Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
CA3018426A1 (en) | 2016-05-13 | 2017-11-16 | Amgen Inc. | Vial sleeve assembly |
WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
GB201609083D0 (en) | 2016-05-24 | 2016-07-06 | Syntab Therapeutics Gmbh | Synthetic compound |
US11541176B2 (en) | 2016-06-03 | 2023-01-03 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
US11285266B2 (en) | 2016-07-01 | 2022-03-29 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
US20200261643A1 (en) | 2016-10-25 | 2020-08-20 | Amgen Inc. | On-body injector |
WO2018136398A1 (en) | 2017-01-17 | 2018-07-26 | Amgen Inc. | Injection devices and related methods of use and assembly |
WO2018151890A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
AU2018221351B2 (en) | 2017-02-17 | 2023-02-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
CA3050927A1 (en) | 2017-03-06 | 2018-09-13 | Brian Stonecipher | Drug delivery device with activation prevention feature |
US11571511B2 (en) | 2017-03-07 | 2023-02-07 | Amgen Inc. | Insertion mechanism and method of inserting a needle of a drug delivery device |
IL268386B2 (en) | 2017-03-09 | 2023-11-01 | Amgen Inc | Insertion mechanism for a drug delivery device |
EP3570871B1 (en) | 2017-03-20 | 2020-11-18 | H. Hoffnabb-La Roche Ag | Method for in vitro glycoengineering of an erythropoiesis stimulating protein |
FI3600491T3 (fi) | 2017-03-28 | 2023-10-20 | Amgen Inc | Männänvarren ja ruiskukokoonpanon järjestelmä ja menetelmä |
CA3066399A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Torque driven drug delivery device |
AU2018280054B2 (en) | 2017-06-08 | 2023-07-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
MX2019015472A (es) | 2017-06-22 | 2020-02-19 | Amgen Inc | Reduccion del impacto/choque de la activacion del mecanismo. |
MA49461A (fr) | 2017-06-23 | 2020-04-29 | Amgen Inc | Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur |
WO2019014014A1 (en) | 2017-07-14 | 2019-01-17 | Amgen Inc. | NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM |
JP2020527376A (ja) | 2017-07-21 | 2020-09-10 | アムジエン・インコーポレーテツド | 薬物容器のためのガス透過性シーリング部材及び組立方法 |
EP3658203B1 (en) | 2017-07-25 | 2022-08-31 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
MA49676A (fr) | 2017-07-25 | 2020-06-03 | Amgen Inc | Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé |
WO2019032482A2 (en) | 2017-08-09 | 2019-02-14 | Amgen Inc. | HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM |
EP3668567A1 (en) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
EP3691717B1 (en) | 2017-10-04 | 2023-02-08 | Amgen Inc. | Flow adapter for drug delivery device |
WO2019070552A1 (en) | 2017-10-06 | 2019-04-11 | Amgen Inc. | DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD |
MA50348A (fr) | 2017-10-09 | 2020-08-19 | Amgen Inc | Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé |
MA50528A (fr) | 2017-11-03 | 2020-09-09 | Amgen Inc | Systèmes et approches pour stériliser un dispositif d'administration de médicament |
CA3079197A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Drug delivery device with placement and flow sensing |
MA50569A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Ensembles de remplissage-finition et procédés associés |
WO2019094138A1 (en) | 2017-11-10 | 2019-05-16 | Amgen Inc. | Plungers for drug delivery devices |
CN111278487B (zh) | 2017-11-16 | 2022-06-24 | 安进公司 | 用于药物递送装置的门闩锁机构 |
MA50903A (fr) | 2017-11-16 | 2021-05-12 | Amgen Inc | Auto-injecteur avec détection de décrochage et de point d'extrémité |
US10679942B2 (en) * | 2018-03-15 | 2020-06-09 | International Business Machines Corporation | Electrical junction for facilitating an integration of electrical crossing |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
CN112351804A (zh) | 2018-07-24 | 2021-02-09 | 安进公司 | 用于施用药物的输送装置 |
CA3103681A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
US20210228815A1 (en) | 2018-07-24 | 2021-07-29 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
CA3103105A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
CA3106452A1 (en) | 2018-09-24 | 2020-04-02 | Amgen Inc. | Interventional dosing systems and methods |
AU2019350660A1 (en) | 2018-09-28 | 2021-03-18 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
WO2020072577A1 (en) | 2018-10-02 | 2020-04-09 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
CA3112214A1 (en) | 2018-10-05 | 2020-04-09 | Amgen Inc. | Drug delivery device having dose indicator |
CN112689523A (zh) | 2018-10-15 | 2021-04-20 | 安进公司 | 用于药物递送装置的平台组装方法 |
EA202191037A1 (ru) | 2018-10-15 | 2021-08-05 | Эмджен Инк. | Устройство доставки лекарственного средства, имеющее демпферный механизм |
MA54057A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament |
US20220031953A1 (en) | 2018-11-01 | 2022-02-03 | Amgen Inc. | Drug delivery devices with partial needle retraction |
EP3873566A1 (en) | 2018-11-01 | 2021-09-08 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
CN109776359B (zh) * | 2019-03-07 | 2021-03-09 | 暨明医药科技(苏州)有限公司 | 一种Boc-1-氨基-3,6-二氧杂-1,8-辛二胺的合成工艺 |
JP2022529319A (ja) | 2019-04-24 | 2022-06-21 | アムジエン・インコーポレーテツド | シリンジ滅菌確認アセンブリ及び方法 |
AU2020337250A1 (en) | 2019-08-23 | 2022-03-03 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
WO2022246055A1 (en) | 2021-05-21 | 2022-11-24 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
US4677195A (en) * | 1985-01-11 | 1987-06-30 | Genetics Institute, Inc. | Method for the purification of erythropoietin and erythropoietin compositions |
US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5006333A (en) * | 1987-08-03 | 1991-04-09 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
WO1990008822A1 (en) * | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
DE69026306T2 (de) | 1989-05-27 | 1996-10-17 | Sumitomo Pharma | Verfahren für die Herstellung von Polyethylenglykolderivate und modifizierte Proteine. |
US5292654A (en) * | 1990-12-13 | 1994-03-08 | Whitehead Institute For Biomedical Research | Mutant EPO receptor and uses therefor |
EP0575545B1 (en) | 1991-03-15 | 2003-05-21 | Amgen Inc. | Pegylation of polypeptides |
JPH06506217A (ja) | 1991-03-18 | 1994-07-14 | エンゾン,インコーポレーテッド | ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体 |
US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
US6153407A (en) * | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5773569A (en) * | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5830851A (en) * | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
US5919758A (en) * | 1994-03-22 | 1999-07-06 | Beth Israel Deaconess Medical Center | Modified polypeptides with altered biological activity |
US5580853A (en) * | 1994-03-22 | 1996-12-03 | New England Deaconess Hospital | Modified polypeptides with increased biological activity |
US5747446A (en) * | 1994-03-22 | 1998-05-05 | Beth Israel Deaconess Medical Center | Modified polypeptides with increased biological activity |
US5767078A (en) * | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
US5654276A (en) * | 1995-06-07 | 1997-08-05 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US5668110A (en) * | 1995-06-07 | 1997-09-16 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
DE69637473T2 (de) * | 1995-06-07 | 2009-05-07 | Glaxo Group Ltd., Greenford | An einem thrombopoietin rezeptor bindende peptide und zusammensetzungen |
US5677280A (en) * | 1995-06-07 | 1997-10-14 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
US5683983A (en) * | 1995-06-07 | 1997-11-04 | Glaxo Group Limited | Peptides and compounds that bind to the IL-5 receptor |
US6251864B1 (en) * | 1995-06-07 | 2001-06-26 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
PL185040B1 (pl) * | 1995-06-07 | 2003-02-28 | Affymax Tech Nv | Peptyd wiążący się z receptorami erytropoetyny, kompozycja farmaceutyczna zawierająca ten peptyd i jego zastosowanie do wytwarzania środka leczniczego |
WO1996040189A1 (en) | 1995-06-07 | 1996-12-19 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US6346390B1 (en) * | 1996-03-08 | 2002-02-12 | Receptron, Inc. | Receptor derived peptides involved in modulation of response to ligand binding |
US7091311B2 (en) * | 1996-06-07 | 2006-08-15 | Smithkline Beecham Corporation | Peptides and compounds that bind to a receptor |
US6103879A (en) * | 1996-06-21 | 2000-08-15 | Axys Pharmaceuticals, Inc. | Bivalent molecules that form an activating complex with an erythropoietin receptor |
SI0964702T1 (sl) * | 1996-08-02 | 2007-02-28 | Ortho Mcneil Pharm Inc | Polipeptidi, ki imajo posamezen kovalentno vezan N-terminalni vodotopni polimer |
US5932546A (en) * | 1996-10-04 | 1999-08-03 | Glaxo Wellcome Inc. | Peptides and compounds that bind to the thrombopoietin receptor |
US6221608B1 (en) * | 1997-01-22 | 2001-04-24 | Ortho Pharmaceutical Corporation | Methods for identifying erythropoietin receptor binding protein |
JPH114133A (ja) * | 1997-06-12 | 1999-01-06 | Murata Mfg Co Ltd | 厚み縦圧電共振子 |
US6211608B1 (en) * | 1998-06-11 | 2001-04-03 | Micron Technology, Inc. | Field emission device with buffer layer and method of making |
US6783965B1 (en) * | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
BRPI9917760B8 (pt) | 1998-08-06 | 2021-05-25 | Univ Duke | método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada |
DK2316475T3 (da) * | 1998-08-06 | 2017-11-20 | Mountain View Pharmaceuticals Inc | Isoleret tetramer urikase |
EP1008355A1 (en) | 1998-12-08 | 2000-06-14 | Debio Recherche Pharmaceutique S.A. | Method for identifying or analyzing polymer linkage sites on macromolecules using amino acid report binding |
JP2002528562A (ja) | 1998-08-28 | 2002-09-03 | グリフォン サイエンシーズ | 長さのばらつきが小さいポリアミド連鎖、その連鎖の製造方法およびその連鎖とタンパク質の複合体 |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
DE69934425T2 (de) | 1998-10-23 | 2007-09-27 | Amgen Inc., Thousand Oaks | Thrombopoietin substitute |
US6498155B1 (en) * | 1998-11-17 | 2002-12-24 | Smithkline Beecham Corporation | Methods of treating thrombocytopenia |
JO2291B1 (en) * | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
AUPQ873300A0 (en) * | 2000-07-12 | 2000-08-03 | Medvet Science Pty. Ltd. | A binding motif of a receptor (2) |
US6552008B1 (en) * | 1999-09-24 | 2003-04-22 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
ES2254224T3 (es) * | 1999-09-27 | 2006-06-16 | Chugai Seiyaku Kabushiki Kaisha | Nueva proteina del receptor de hematopoyetina, nr12. |
US6703480B1 (en) | 1999-11-24 | 2004-03-09 | Palani Balu | Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use |
US6858630B2 (en) * | 1999-12-06 | 2005-02-22 | Smithkline Beecham Corporation | Naphthimidazole derivatives and their use as thrombopoietin mimetics |
US7109299B1 (en) * | 1999-12-16 | 2006-09-19 | Affymax, Inc. | Peptides and compounds that bind to the IL-5 receptor |
WO2001071309A2 (en) * | 2000-03-21 | 2001-09-27 | Wisconsin Alumni Research Foundation | Methods and reagents for regulation of cellular responses in biological systems |
US6777387B2 (en) * | 2000-03-31 | 2004-08-17 | Enzon Pharmaceuticals, Inc. | Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same |
HU230874B1 (hu) * | 2000-05-15 | 2018-11-29 | F. Hoffmann-La Roche Ag | Pegilezett humán eritropoietin-fehérjét tartalmazó, szobahőmérsékleten stabil folyékony gyógyászati készítmények |
NZ522924A (en) | 2000-05-26 | 2004-12-24 | Ortho Mcneil Pharm Inc | Neuroprotective peptides |
WO2002010743A1 (en) * | 2000-08-02 | 2002-02-07 | Ortho-Mcneil Pharmaceutical, Inc. | Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin |
WO2002019963A2 (en) * | 2000-09-08 | 2002-03-14 | Gryphon Therapeutics, Inc. | Synthetic erythropoiesis stimulating proteins |
AU3323002A (en) * | 2000-12-20 | 2002-07-01 | Hoffmann La Roche | Erythropoietin conjugates |
US6531121B2 (en) * | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
US7767643B2 (en) * | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
MXPA03007392A (es) | 2001-02-20 | 2003-12-04 | Enzon Inc | Enlazantes polimericos ramificados terminalmente y conjugados polimericos que contienen los mismos. |
FR2823220B1 (fr) * | 2001-04-04 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo) |
US20020169128A1 (en) * | 2001-04-09 | 2002-11-14 | Geroge Sigounas | Erythropoietin ameliorates chemotherapy-induced toxicity in vivo |
WO2003002716A2 (en) | 2001-06-28 | 2003-01-09 | Mountain View Pharmaceuticals, Inc. | Polymer stabilized proteinases |
US6784154B2 (en) * | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
US20050176627A1 (en) * | 2002-09-09 | 2005-08-11 | Anthony Cerami | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
US8129330B2 (en) * | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US20040062748A1 (en) | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
EP1667708B9 (en) * | 2002-12-26 | 2012-10-31 | Mountain View Pharmaceuticals, Inc. | POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY |
EA013535B1 (ru) | 2002-12-26 | 2010-06-30 | Маунтин Вью Фамэсьютикэлс, Инк. | Полимерный конъюгат биоактивного компонента (варианты), способ его получения и использования, фармацевтические продукты на его основе |
WO2004101606A2 (en) * | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
-
2004
- 2004-05-12 KR KR1020057021602A patent/KR101227666B1/ko not_active IP Right Cessation
- 2004-05-12 KR KR1020127014202A patent/KR20120094001A/ko not_active Application Discontinuation
- 2004-05-12 ES ES04760995T patent/ES2395413T3/es active Active
- 2004-05-12 NZ NZ543935A patent/NZ543935A/en not_active IP Right Cessation
- 2004-05-12 CN CN2004800199359A patent/CN1823088B/zh not_active Expired - Fee Related
- 2004-05-12 AU AU2004238868A patent/AU2004238868B2/en not_active Ceased
- 2004-05-12 PL PL04760995T patent/PL1625156T3/pl unknown
- 2004-05-12 MX MXPA05012313A patent/MXPA05012313A/es active IP Right Grant
- 2004-05-12 SI SI200431975T patent/SI1625156T1/sl unknown
- 2004-05-12 DK DK04760995.3T patent/DK1625156T3/da active
- 2004-05-12 EA EA200501798A patent/EA010099B1/ru not_active IP Right Cessation
- 2004-05-12 CA CA002525497A patent/CA2525497A1/en not_active Abandoned
- 2004-05-12 WO PCT/US2004/014886 patent/WO2004101611A2/en active Application Filing
- 2004-05-12 US US10/555,868 patent/US7528104B2/en not_active Expired - Fee Related
- 2004-05-12 EP EP04760995A patent/EP1625156B1/en active Active
- 2004-05-12 JP JP2006532997A patent/JP4949844B2/ja not_active Expired - Fee Related
- 2004-05-12 PT PT47609953T patent/PT1625156E/pt unknown
- 2004-05-12 BR BRPI0411172-9A patent/BRPI0411172A/pt not_active IP Right Cessation
-
2005
- 2005-12-02 IS IS8167A patent/IS8167A/is unknown
- 2005-12-08 ZA ZA200509971A patent/ZA200509971B/en unknown
- 2005-12-09 NO NO20055847A patent/NO20055847L/no not_active Application Discontinuation
-
2006
- 2006-08-14 HK HK06109023.6A patent/HK1088906A1/xx not_active IP Right Cessation
-
2009
- 2009-03-17 US US12/405,599 patent/US8304391B2/en not_active Expired - Fee Related
- 2009-05-20 IL IL198844A patent/IL198844A0/en unknown
-
2012
- 2012-10-18 US US13/654,507 patent/US20130130979A1/en not_active Abandoned
- 2012-11-01 US US13/666,579 patent/US20130244939A1/en not_active Abandoned
- 2012-12-03 HR HRP20120989TT patent/HRP20120989T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120989T1 (hr) | Peptidi koji se vežu za receptor eritropoetina | |
Scholl et al. | Dendritic and hyperbranched polyamides | |
Carlsen et al. | Self-assembly of polypeptide-based block copolymer amphiphiles | |
Radvar et al. | Supramolecular peptide/polymer hybrid hydrogels for biomedical applications | |
Deng et al. | Functional polypeptide and hybrid materials: Precision synthesis via α-amino acid N-carboxyanhydride polymerization and emerging biomedical applications | |
Chassenieux et al. | Recent trends in pH/thermo-responsive self-assembling hydrogels: from polyions to peptide-based polymeric gelators | |
BG104570A (en) | Erythropoetin conjugates | |
Luo et al. | Thermoresponsive self‐assembly of nanostructures from a collagen‐like peptide‐containing diblock copolymer | |
Krannig et al. | Emerging bioinspired polymers: glycopolypeptides | |
RS51130B (sr) | Novi peptidi koji se vezuju za eritropoietinski receptor | |
WO1998052614A3 (en) | Composition and method for enhancing transport across biological membranes | |
WO2006090924A1 (ja) | ペプチドリガンドを有するブロック共重合体 | |
CA2355705A1 (fr) | Polyetheresteramides et compositions de polymeres antistatiques les contenant | |
WO2012045822A1 (en) | A thermo-responsive polymer covalently bound with a peptide | |
US20120271003A1 (en) | Block Copolymers As Thermoplastic Elastomers Made Of Polyisobutene Blocks And Oligoamide Blocks | |
Bauer et al. | Secondary structure-driven self-assembly of thiol-reactive polypept (o) ides | |
JP2010520855A5 (hr) | ||
Nieto-Orellana et al. | Effect of polymer topology on non-covalent polymer–protein complexation: Miktoarm versus linear mPEG-poly (glutamic acid) copolymers | |
Khuphe et al. | Poly (amino acids) | |
CN107556497A (zh) | 一种杂化水凝胶材料的制备方法及应用 | |
Huang et al. | Polypeptide–poly (ethylene glycol) miktoarm star copolymers with a fluorescently labeled core: Synthesis, delivery and imaging of siRNA | |
Ma et al. | Development of polypeptide-based zwitterionic amphiphilic micelles for nanodrug delivery | |
Gao et al. | In situ growth of a thermoresponsive polymer from a genetically engineered elastin-like polypeptide | |
Garanger et al. | Emerging opportunities in bioconjugates of Elastin-like polypeptides with synthetic or natural polymers | |
JP2007504169A5 (hr) |